Beyond anemia, how can CKD affect hematologic status?

• A. Platelet dysfunction, contributing to bleeding tendencies and increased cardiovascular risk.
• B. No hematologic changes.
• C. Hypercoagulable state with no bleeding.
• D. Increased RBC production.

Answer: (A)

Beyond anemia, kidney disease commonly disrupts platelet function due to uremic toxins, which impairs how platelets adhere to vessel walls and aggregate at injury sites. This leads to a bleeding tendency that can manifest as easy bruising, mucosal bleeding, or prolonged bleeding during procedures, even when standard coagulation tests (like PT or aPTT) are normal. This platelet dysfunction also contributes to cardiovascular risk in CKD patients because it reflects an overall hemostatic imbalance and can complicate invasive therapies or dialysis access.

The other ideas don’t fit as well because CKD does cause hematologic changes beyond anemia, so saying there are no changes isn’t accurate. While CKD can be associated with thrombotic events in some contexts, the most characteristic hematologic issue beyond low red cells is impaired platelet function leading to bleeding tendencies. Increased RBC production does not occur in CKD; erythropoietin production is reduced, contributing to anemia instead.